

SUMMARY PLAN DESCRIPTION LANGUAGE

Summary Plan Description Language: Healthy Pregnancy (Screening, Testing, Counseling, Preventive Medication, and Treatment)

Human Immunodeficiency Virus (HIV) (Screening)

Covered Screening

All FDA-licensed screens and tests, including:

- Enzyme immunoassay (EIA)
- Western blot test
- Abbott Murex Single Use Diagnostic System HIV-1 test
- Rapid assay test

Initiation, Cessation, and Interval

All pregnant women are eligible for HIV screening. One-time screening is covered for normal-risk women and should be conducted as early as possible during the pregnancy. All pregnant women with a positive screen are eligible for confirmatory testing. Women at high risk of HIV infection are eligible for additional screening/confirmatory testing during the third trimester, or as medically indicated.

Summary Plan Description Language: Human Immunodeficiency Virus (HIV) (Counseling)

Covered Counseling

Counseling regarding HIV screening and HIV test results, risk reduction, and transmission reduction is a covered benefit for all pregnant women.

Initiation, Cessation, and Interval

All pregnant women are eligible to receive counseling and educational information on HIV and HIV screening before they are screened.

All pregnant women who are screened for HIV are eligible for post-test counseling on their result and risk reduction.

Pregnant women who have behaviors that place them at high risk for acquiring HIV infection (e.g., multiple sex partners, history of STDs, substance abuse, etc) are eligible for a referral to an HIV risk-reduction service (e.g., HIV centers with personnel trained in HIV counseling, drug treatment centers, etc).

Summary Plan Description Language: Human Immunodeficiency Virus (HIV) (Preventive Medication)

Covered Preventive Medications

Antiretroviral chemoprophylaxis is a covered benefit for all infant beneficiaries who are born to women who are HIV positive or whose HIV status is unknown at the time of labor and delivery.

Initiation, Cessation, and Interval

All FDA-approved medications used for the prevention of perinatal HIV transmission are covered, as prescribed by a clinician, for exposed infants during the first 6 weeks of life (or as medically indicated).